Universe Pharmaceuticals (Universe Pharmaceuticals) EV-to-EBIT : 1.16 (As of May. 27, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Universe Pharmaceuticals EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Universe Pharmaceuticals's Enterprise Value is $-4.27 Mil. Universe Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-3.69 Mil. Therefore, Universe Pharmaceuticals's EV-to-EBIT for today is 1.16.

The historical rank and industry rank for Universe Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

UPC' s EV-to-EBIT Range Over the Past 10 Years
Min: -2.93 Med: 0.98 Max: 10.06
Current: 1.16

During the past 6 years, the highest EV-to-EBIT of Universe Pharmaceuticals was 10.06. The lowest was -2.93. And the median was 0.98.

UPC's EV-to-EBIT is ranked better than
96.28% of 672 companies
in the Drug Manufacturers industry
Industry Median: 16.985 vs UPC: 1.16

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Universe Pharmaceuticals's Enterprise Value for the quarter that ended in Sep. 2023 was $-9.56 Mil. Universe Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-3.69 Mil. Universe Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 38.63%.

Universe Pharmaceuticals EV-to-EBIT Historical Data

The historical data trend for Universe Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Universe Pharmaceuticals EV-to-EBIT Chart

Universe Pharmaceuticals Annual Data

Trend

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

EV-to-EBIT

Get a 7-Day Free Trial

2.63

0.34

2.59

Universe Pharmaceuticals Semi-Annual Data
	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
EV-to-EBIT	Get a 7-Day Free Trial						2.63	-	0.34	-	2.59

Competitive Comparison of Universe Pharmaceuticals's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Universe Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Universe Pharmaceuticals's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Universe Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Universe Pharmaceuticals's EV-to-EBIT falls into.

Universe Pharmaceuticals EV-to-EBIT Calculation

Universe Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	-4.271	/	-3.692
	=	1.16

Universe Pharmaceuticals's current Enterprise Value is $-4.27 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Universe Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-3.69 Mil.

Universe Pharmaceuticals (NAS:UPC) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Universe Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2023 )	=	EBIT	/	Enterprise Value (Q: Sep. 2023 )
	=	-3.692	/	-9.5583285
	=	38.63 %

Universe Pharmaceuticals's Enterprise Value for the quarter that ended in Sep. 2023 was $-9.56 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Universe Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-3.69 Mil.

Universe Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Universe Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Universe Pharmaceuticals (Universe Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Universe Pharmaceuticals Inc (NAS:UPC) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

265 Jingjiu Avenue, Economic & Technological Development Zone, Jinggangshan, Jiangxi, Ji’an, CHN

Website

http://www.universe-pharmacy.com

Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications.